Obesity and prostate cancer screening among african-american and caucasian men
- 15 September 2006
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 66 (13) , 1371-1380
- https://doi.org/10.1002/pros.20377
Abstract
BACKGROUND Differential prostate‐specific antigen (PSA) testing practices according to obesity‐related comorbid conditions may contribute to inconsistent results in studies of obesity and prostate cancer. We investigated the relationship between obesity and PSA testing, and evaluated the role of prior diagnoses and disease screening on PSA testing patterns. METHODS Men, 40 and 79 years old and without prior prostate cancer were recruited from 25 health centers in the Southern US (n = 11,558, 85% African‐American). An extensive in‐person interview measured medical and other characteristics of study participants, including PSA test histories, weight, height, demographics, and disease history. Odds ratios (OR) and (95% confidence intervals) from logistic regression summarized the body mass index (BMI) and PSA test association while adjusting for socio‐economic status (SES). RESULTS BMI between 25 and 40 was significantly associated with recent PSA testing (past 12 months) (OR25.0–29.9 = 1.23 (1.09, 1.39); OR30–34.9 = 1.36 (1.18, 1.57); OR35.0–39.9 = 1.44 (1.18, 1.76); OR≥40 = 1.15 (0.87, 1.51)). Prior severe disease diagnoses, such as heart disease, did not influence the obesity and PSA test association. However, adjustment for prior high blood pressure or high cholesterol diagnoses reduced the BMI‐PSA testing associations. Physician PSA test recommendations were not associated with BMI, and results did not appreciably vary by race. CONCLUSIONS Overweight and obese men were preferentially PSA tested within the past 12 months. BMI was not associated with physician screening recommendations. Data suggest that clinical diagnoses related to obesity increase clinical encounters that lead to preferential selection of obese men for prostate cancer diagnosis. This detection effect may bias epidemiologic investigations of obesity and prostate cancer incidence. Prostate 66: 1371–1380, 2006.Keywords
This publication has 31 references indexed in Scilit:
- Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and ResistinClinical Chemistry, 2004
- Resistin, Adiponectin, Ghrelin, Leptin, and Proinflammatory Cytokines: Relationships in ObesityObesity Research, 2004
- Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study GroupJournal of Clinical Oncology, 2004
- Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical ProstatectomyJournal of Clinical Oncology, 2004
- Hormones and Prostate Cancer: What's Next?Epidemiologic Reviews, 2001
- Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective StudyJNCI Journal of the National Cancer Institute, 2000
- Screening for Cervical and Breast Cancer: Is Obesity an Unrecognized Barrier to Preventive Care?Annals of Internal Medicine, 2000
- Body Size and Prostate Cancer: A 20-Year Follow-up Study Among 135006 Swedish Construction WorkersJNCI Journal of the National Cancer Institute, 1997
- Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States)Cancer Causes & Control, 1997
- A prospective study of weight, body mass index and other anthropometric measurements in relation to site‐specific cancersInternational Journal of Cancer, 1994